Endocrine Neoplasia Clinical Trials

1 recruiting

Endocrine Neoplasia Trials at a Glance

10 actively recruiting trials for endocrine neoplasia are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in Houston, Bethesda, and Buenos Aires. Lead sponsors running endocrine neoplasia studies include M.D. Anderson Cancer Center, J.M. de Laat, and Hospital Italiano de Buenos Aires.

Browse endocrine neoplasia trials by phase

Treatments under study

About Endocrine Neoplasia Clinical Trials

Looking for clinical trials for Endocrine Neoplasia? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Endocrine Neoplasia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Endocrine Neoplasia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting
Phase 1

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

Endocrine Neoplasia
M.D. Anderson Cancer Center55 enrolled1 locationNCT05335811
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting
Phase 3

PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)

Neuroendocrine Neoplasia's (NENs)Neuroendocrine Gastroenteropancreatic TumourNeuroendocrine Tumor GEP Grade 1-3
Tata Memorial Hospital162 enrolled2 locationsNCT07185672
Recruiting
Not Applicable

Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients

Multiple Endocrine Neoplasia Type 1Neuroendocrine Tumor of Pancreas
J.M. de Laat20 enrolled1 locationNCT05037461
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Neuroendocrine NeoplasmParagangliomaPheochromocytoma+23 more
Universidad Nacional Autonoma de Mexico750 enrolled3 locationsNCT06523582
Recruiting
Early Phase 1

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland16 enrolled1 locationNCT05359146
Recruiting

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

Multiple Endocrine Neoplasia
M.D. Anderson Cancer Center629 enrolled1 locationNCT03048266
Recruiting

Study and Follow-up of Multiple Endocrine Neoplasia Type 1

Multiple Endocrine Neoplasia
Centre Hospitalier Universitaire Dijon2,000 enrolled1 locationNCT03348501